ADALIMUMAB
adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices
ADALIMUMAB (9426D)
9426D
Manner of administration:Injection
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 1, Whole body (new patient)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 2, Whole body (change or recommencement of treatment after
a break in biological medicine of less than 5 years)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 3, Whole body (recommencement of treatment after a break
in biological medicine of more than 5 years)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 1, Face, hand, foot (new patient)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 2, Face, hand, foot (change or recommencement of treatment
after a break in biological medicine of less than 5 years)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 3, Face, hand, foot (recommencement of treatment after
a break in biological medicine of more than 5 years)
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Balance of supply - Initial treatment - Initial 1, Whole body or Face, hand, foot
(new patient) or Initial 2, Whole body or Face, hand, foot (change or recommencement
of treatment after a break in biological medicine of less than 5 years) or Initial
3, Whole body or Face, hand, foot (recommencement of treatment after a break in biological
medicine of more than 5 years)